Summer 2026 has produced an unusual public health picture on the CDC Travel Health Notices page: three simultaneous active travel notices for chikungunya — the mosquito-borne virus known for causing weeks of debilitating joint pain — across three different geographic regions. Suriname, a country on the northeastern coast of South America, has had an active chikungunya outbreak since February 2026. Mayotte, a French territory in the Indian Ocean off the coast of Mozambique, has been under a CDC chikungunya notice since March 10, 2026. And French Guiana, the French overseas territory on the northern coast of South America adjacent to Brazil, received a new CDC travel notice for chikungunya on June 4, 2026 — just 10 days ago.
Three simultaneous active outbreaks across two continents and the Indian Ocean, all in destinations that receive American travelers during peak summer season, all involving the same virus, and all preventable by a vaccine that most American travelers have never heard of.
Chikungunya is caused by the chikungunya alphavirus, transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes — the same species responsible for dengue fever and Zika virus transmission. It cannot spread person to person. It requires a mosquito bite for transmission, which means travelers who effectively prevent mosquito bites can protect themselves. But unlike dengue — for which no reliably effective, widely available vaccine existed in the U.S. until recently — chikungunya now has an FDA-approved single-dose vaccine that provides broad, durable protection.
The Pattern of These Three Simultaneous Outbreaks
The geographic distribution of the three current CDC chikungunya notices reflects distinct but parallel epidemiological situations. In Suriname, chikungunya has been circulating since at least February 2026, consistent with the country’s tropical climate that supports year-round Aedes mosquito activity. Suriname borders Guyana to the west, Brazil to the south, and French Guiana to the east — meaning outbreak activity in Suriname creates risk for cross-border spread to adjacent territories, and the French Guiana notice issued June 4 is likely connected to regional transmission dynamics that began in Suriname and Brazil.
Mayotte’s chikungunya outbreak is separate in origin — the island’s subtropical Indian Ocean climate creates independent conditions for Aedes activity, and chikungunya has a well-documented history of large outbreak cycles in Indian Ocean territories, including the catastrophic 2005–2006 outbreak in La Réunion that infected nearly one-third of the island’s population.
What these three outbreaks share is the presence of Aedes aegypti or Aedes albopictus at epidemic transmission levels, a population of susceptible individuals without prior immunity, and the current arrival of the summer travel season, which increases the probability of importation to the United States via returning travelers.
What Chikungunya Does to the Human Body
The word chikungunya comes from the Makonde language of Tanzania, meaning “that which bends up” — a reference to the stooped posture that patients adopt in response to severe joint pain. The description is medically accurate and experientially unforgettable. After an incubation period of 2 to 12 days following a mosquito bite, patients develop sudden high fever — often above 103°F — accompanied by polyarthralgia, the simultaneous severe painful inflammation of multiple joints. The hands, wrists, ankles, and feet are most commonly affected, and the pain is frequently described by patients as worse than anything they have experienced. Many cannot walk, dress, or grip a cup.
The acute phase typically lasts 7 to 10 days. Most patients recover. But approximately 25 to 50 percent of people infected with chikungunya develop chronic post-chikungunya arthritis — persistent joint pain that continues for months to years after the initial infection has resolved. This is the longest-lasting and most debilitating consequence of chikungunya, and it disproportionately affects older adults and those with pre-existing joint disease.
The Vaccine That Travelers Are Not Getting
The FDA approved Ixchiq (chikungunya vaccine) in November 2023 for adults 18 and older at increased risk of chikungunya exposure. Ixchiq is a live-attenuated, single-dose vaccine that requires no booster and has demonstrated strong immunogenicity and an acceptable safety profile in clinical trials. It is available through travel medicine clinics and many primary care providers.
Despite its approval, Ixchiq remains significantly underutilized among American travelers to chikungunya-endemic and outbreak-affected regions. Awareness of the vaccine’s existence is low among both patients and some general practitioners who do not specialize in travel medicine. Travelers heading to Suriname, French Guiana, Mayotte, or any of the many Caribbean and South American destinations currently experiencing elevated chikungunya activity should specifically ask about Ixchiq at their travel medicine consultation.
The vaccine requires at least 28 days to induce full protection, so travelers should plan accordingly — those departing within 28 days should be advised to rely on intensive mosquito bite prevention while the vaccine becomes effective, or may not benefit from vaccination for their current trip. As with all mosquito-borne disease prevention, repellent use, protective clothing, air conditioning, and bed nets remain essential complements to vaccination.
Frequently Asked Questions
Q: Where are the current chikungunya outbreaks with CDC travel notices?
A: As of June 2026, active CDC chikungunya travel notices cover Suriname (February 2026), Mayotte, a French Indian Ocean territory (March 10, 2026), and French Guiana (June 4, 2026).
Q: What are the symptoms of chikungunya?
A: Sudden high fever and severe polyarthralgia — simultaneous joint pain in multiple joints, especially the hands, wrists, ankles, and feet — beginning 2 to 12 days after a mosquito bite. The pain is frequently described as the worst the patient has ever experienced. Most cases resolve within 7 to 10 days, but 25–50% develop chronic joint pain lasting months to years.
Q: Is there a vaccine for chikungunya?
A: Yes. Ixchiq is an FDA-approved single-dose live-attenuated vaccine for adults 18 and older. It was approved November 2023 and is available at travel medicine clinics. It requires approximately 28 days to become fully effective.
Q: Who should get vaccinated against chikungunya before travel?
A: Adults 18 and older traveling to areas with active chikungunya transmission who will have outdoor exposure to mosquitoes. This currently includes travelers to Suriname, French Guiana, Mayotte, and other active outbreak areas.
Q: How is chikungunya different from dengue fever?
A: Both are transmitted by Aedes mosquitoes and cause fever. Chikungunya is distinguished by the severe arthralgia (joint pain) that dominates its clinical picture and can persist for months to years. Dengue more commonly causes a characteristic rash, severe headache, and potentially hemorrhagic complications.
